In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
We are pleased to announce the launch of UTIPRO® PLUS AF in the Republic of Ireland.
UTIPRO® PLUS AF, in its composition free from ingredients of animal origin, has been recently launched in the Republic of Ireland, thus further enlarging its presence across Europe. The product is distributed by Pamex, an Irish company specialized in the detailing and the distribution of high quality and innovative products, mainly addressed to female health and care. Pamex, through its sales force made of 9 dedicated REPS, will introduce the product across Primary, Secondary, Pharmacy & Specialized Care.
We are proud to announce the publication of the clinical trial “Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.”. While Oral Rehydration (ORS) is the main treatment of acute diarrhea in children, the addition of specific antidiarrheals may speed up the reduction of symptoms. In this clinical trial, children receiving xyloglucan/gelose (vegetal ingredients of Xilaplus AF) on top of the ORS, had significantly fewer diarrheic episodes than those who received ORS alone. The improvement of symptoms in the group on Xyloglucan/gelose was evident from 6 hours after the first dose.
We are glad inform you about a recent publication to further support the usefulness of mucoprotection in the relief of symptoms and in the prevention of recurrences in uncomplicated UTIs
The trial "Xyloglucan + Gelose Combination versus Placebo as Adjuvant Therapy to First-Line Antimicrobials for Uncomplicated Urinary Tract Infection in Adults" has been published on Urologia Internationalis.
https://www.ncbi.nlm.nih.gov/pubmed/30889607
In the study, safety and efficacy of a Xyloglucan based medical device were investigated as adjuvant therapy to first-line antimicrobials for treatment of uncomplicated UTIs in adults.